TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00649766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tailored newsletter
Description: Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: targeted newsletter
Description: Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
Study: NCT02303080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (WPM 0)
Description: 85.0 % maltodextrin,15.0% fat, 0% WPM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (WPM 0)
Description: 85.0 % maltodextrin,15.0% fat, 0% WPM
Study: NCT02170532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aerochamber max

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aerochamber max

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratroprium
Study: NCT02303080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (WPM 0)
Description: 85.0 % maltodextrin,15.0% fat, 0% WPM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WPM 30
Description: 43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WPM 30
Description: 43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WPM 30
Description: 43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
Study: NCT02845453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
Study: NCT02303080

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WPM 50
Description: 16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WPM 50
Description: 16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WPM 50
Description: 16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MC 50
Description: 16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MC 50
Description: 16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MC 50
Description: 16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
Study: NCT00998855

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: 12 wk aerobic or/ resistance exercise program
Study: NCT02098499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 5mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: 10mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: 25mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: 25mg IV
Study: NCT02927704

Intervention type: OTHER
Intervention: Gingival crevicular fluid (GCF) sample
Description: Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.

Intervention type: OTHER
Intervention: Gingival crevicular fluid (GCF) sample
Description: Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
Study: NCT04274049

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
Study: NCT02362516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Study: NCT01772472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: 6 mg/kg intravenously every 3 weeks, 14 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: 3.6 mg/kg intravenously every 3 weeks, 14 cycles
Study: NCT01746849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lupron

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation (TBI)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation (TBI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study: NCT04134117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
Study: NCT03100981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Mindfulness-Based Cognitive Therapy
Description: Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist control
Description: Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient.
Study: NCT01636063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
Study: NCT04077671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF6467 active
Description: CHF6467, is mutated form of the human Nerve Growth Factor (NGF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF6467 active
Description: CHF6467, is mutated form of the human Nerve Growth Factor (NGF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF6467 active
Description: CHF6467, is mutated form of the human Nerve Growth Factor (NGF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF6467 active
Description: CHF6467, is mutated form of the human Nerve Growth Factor (NGF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF6467 active
Description: CHF6467, is mutated form of the human Nerve Growth Factor (NGF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF6467 active
Description: CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
Study: NCT01611363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT02454881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study: NCT02814513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANDAGO
Description: To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
Study: NCT01503944

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-133
Description: 185 MBq
Study: NCT02644122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF1126
Study: NCT03511144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unity Knee™ TKR using measured resection
Description: Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unity Knee™ TKR using ligament balancing
Description: Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
Study: NCT01503944

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-133
Description: 185 MBq

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-133
Description: 185 MBq

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-133
Description: 185 MBq

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-45
Description: 185-370 MBq

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-45
Description: 185-370 MBq

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-45
Description: 185-370 MBq

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-AV-45
Description: 185-370 MBq
Study: NCT02532933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Synthes Attune PS RP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Synthes Attune PS RP
Study: NCT01891695

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 39.6 Gy radiation
Study: NCT02801240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition support product
Description: Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
Study: NCT00678054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
Study: NCT01763216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Road Tour
Description: Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Boatload of Crosswords
Description: Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
Study: NCT03648060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital kinematic biofeedback system
Description: The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
Study: NCT02662946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG- angiography
Description: Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No angiography
Description: Extension of resection based on subjective measures
Study: NCT04565860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)
Description: Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)
Description: Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)
Description: Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)
Description: Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations).
Study: NCT02326025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV
Study: NCT03236740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol-cyprosterone acetate
Description: Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
Study: NCT04367220

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic testing performed as per routine care
Study: NCT01454622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study: NCT01265290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated 24 hours ECG Holter monitoring
Description: repeated 24 hours ECG Holter monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemetric ECG monitoring
Description: Telemetric ECG full disclosure monitoring with GSM technology
Study: NCT03528993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise by hippotherapy device
Description: Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional rehabilitation
Description: Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).

Intervention type: OTHER
Group type: OTHER
Intervention: postural control exercises
Description: perturbation on four directions, weight bearing exercises on standing positions
Study: NCT02278198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
Study: NCT01401270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management
Description: Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management
Description: Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management
Description: Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management
Description: Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management
Description: Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
Study: NCT00976092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 60 mg prasugrel as loading dose prior to PPCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
Study: NCT02266927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent HFA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPTINOSE™ FLUTICASONE
Study: NCT02646618

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Get Social
Description: Online-delivered weight loss intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Group-delivered weight loss intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
Study: NCT00976092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg clopidogrel as loading dose before PPCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: i.v. bolus of 70-100 IU/kg body weight
Study: NCT03578601

Intervention type: OTHER
Intervention: Thyroid surgery
Description: Patient undergoing thyroid surgery